ASPIRE was a multicentre, randomised, double-blind, placebo-controlled clinical trial. The trial aimed to determine the safety and efficacy of low-dose aspirin to prevent the recurrence of venous thromboembolism (a blood clot in the leg or lungs) in patients with a previous unprovoked thromboembolism.

See ANZCTR for full trial details >

 

Trial Summary:

To determine whether low-dose aspirin is superior to placebo for the prevention of recurrent symptomatic venous thromboembolism (VTE) in patients with unprovoked VTE initially treated with heparin and warfarin. Secondary aims of the study include examining the safety of long-term low-dose aspirin in patients with unprovoked VTE, assessing the effect of therapy on long-term morbidity (postphlebitic syndrome) and assessing the cost-effectiveness of aspirin therapy.

Supported By:

NHMRC, NZ HRC

Eligibility:

Patients with first unprovoked VTE (pulmonary embolism or deep vein thrombosis).

Registration ID:

ACTRN012605000004662

Participation:

The CTC is the international coordinating centre. There are sites in Australia, New Zealand, Singapore, India and Argentina

Australian Lead Group:

NHMRC CTC

Status:

Closed (results published 04/11/2012)

Activation Date:

01/05/2003

Chairs:

Co-principal investigators: Dr John Eikelboom, McMaster Clinic, Hamilton, Canada, and Dr Timothy Brighton, Prince of Wales Hospital, Sydney, NSW Study chair: Professor John Simes, NHMRC CTC

Contact:

aspire@ctc.usyd.edu.au